Three-year follow-up of protease inhibitor-based regimen simplification in HIV-infected patients.
Patients with sustained virological suppression on protease inhibitor (PI)-based therapy were randomly assigned to switch the PI to nevirapine (n = 155), efavirenz (n = 156), or abacavir (n = 149) and were followed for at least 3 years regardless of the discontinuation of assigned therapy. There was a higher probability of maintaining virological suppression after 3 years of follow-up with nevirapine or efavirenz than with abacavir. In contrast, abacavir showed a lower incidence of adverse effects leading to drug discontinuation.
Martínez
Esteban
E
Hospital Clínic, Barcelona, Spain.
Arnaiz
Juan A
JA
Podzamczer
Daniel
D
Dalmau
David
D
Ribera
Esteban
E
Domingo
Pere
P
Knobel
Hernando
H
Leyes
Maria
M
Pedrol
Enric
E
Force
Luís
L
de Lazzari
Elisa
E
Gatell
José M
JM
D000480:Alkynes; D023241:Antiretroviral Therapy, Highly Active / Q000379:methods; D048588:Benzoxazines / Q000627:therapeutic use; D003521:Cyclopropanes; D015224:Dideoxynucleosides / Q000627:therapeutic use; D018450:Disease Progression; D015658:HIV Infections / Q000188:drug therapy* / Q000821:virology; D017320:HIV Protease Inhibitors / Q000627:therapeutic use*; D015497:HIV-1; D006801:Humans; D019829:Nevirapine / Q000627:therapeutic use; D018894:Reverse Transcriptase Inhibitors / Q000627:therapeutic use; D016896:Treatment Outcome; D000099227:Abacavir
D000480:Alkynes; D048588:Benzoxazines; D003521:Cyclopropanes; D015224:Dideoxynucleosides; D017320:HIV Protease Inhibitors; D019829:Nevirapine; D018894:Reverse Transcriptase Inhibitors; D000099227:Abacavir; C098320:efavirenz